ES2123177T3 - Preparacion de absorcion percutanea que contiene buprenorfina. - Google Patents

Preparacion de absorcion percutanea que contiene buprenorfina.

Info

Publication number
ES2123177T3
ES2123177T3 ES95106861T ES95106861T ES2123177T3 ES 2123177 T3 ES2123177 T3 ES 2123177T3 ES 95106861 T ES95106861 T ES 95106861T ES 95106861 T ES95106861 T ES 95106861T ES 2123177 T3 ES2123177 T3 ES 2123177T3
Authority
ES
Spain
Prior art keywords
buprenorphine
percutaneous absorption
penetration enhancer
absorption preparation
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95106861T
Other languages
English (en)
Inventor
Shoichi Tokuda
Kazuhisa Ninomiya
Yasuhiro Fukushima
Shigeyuki Watanabe
Mitsuru Ochiai
Mutsuo Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Nitto Denko Corp
Original Assignee
Nikken Chemicals Co Ltd
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikken Chemicals Co Ltd, Nitto Denko Corp filed Critical Nikken Chemicals Co Ltd
Application granted granted Critical
Publication of ES2123177T3 publication Critical patent/ES2123177T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE HA OBTENIDO UNA PREPARACION DE ABSORCION PERCUTANEA QUE ES EXCELENTE PARA LA PENETRACION EN LA PIEL DE UNA BUPRENORFINA ANALGESICA NO-NARCOTICA Y PUEDE MANTENER UN NIVEL DE SANGRE ALTO EN UN ESTADO ESTABLE POR ENCIMA DE UN LARGO PERIODO DE TIEMPO. LA PREPARACION DE ABSORCION PERCUTANEA PARA ADMINISTRAR HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA, CONTIENE UN SOPORTE QUE TIENE EN UNA SUPERFICIE DEL MISMO UNA CAPA DE ESCAYOLA QUE CONTIENE UN ADHESIVO SENSIBLE A LA PRESION, HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA, UN INTENSIFICADOR DE LA PENETRACION, EN DICHO INTENSIFICADOR DE LA PENETRACION SE CONTIENE UNA COMBINACION DE DE UN MONOGLICERIDO DE UN ACIDO GRASO QUE TIENE DE 6 A 8 ATOMOS DE CARBONO Y MIRISTATO DE ISOPROPILO, Y LA CAPA DE ESCAYOLA CONTIENE AL MENOS EL 10 DE SU PESO DE UN MONOGLICERIDO O ACIDO GRASO QUE TIENE DE 6 A 8 ATOMOS DE CARBONO Y AL MENOS 5 DEL PESO DE MIRISTATO DE ISOPROPILO, CON LA CONDICION DE QUE EL CONTENIDO DE TODO EL INTENSIFICADOR DE PENETRACION OSCILE ENTRE EL 25 Y EL 50 DEL PESO. EL USO COMBINADO DEL MONOGLICERIDO DE ACIDO GRASO Y EL MIRISTATO DE ISOPROPILO COMO INTENSIFICADOR DE LA PENETRACION SINERGETICAMENTE ELEVAN LA PENETRACION EN LA PIEL DEL HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA.
ES95106861T 1994-05-06 1995-05-05 Preparacion de absorcion percutanea que contiene buprenorfina. Expired - Lifetime ES2123177T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6094241A JP2819236B2 (ja) 1994-05-06 1994-05-06 経皮吸収製剤

Publications (1)

Publication Number Publication Date
ES2123177T3 true ES2123177T3 (es) 1999-01-01

Family

ID=14104817

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95106861T Expired - Lifetime ES2123177T3 (es) 1994-05-06 1995-05-05 Preparacion de absorcion percutanea que contiene buprenorfina.

Country Status (10)

Country Link
US (1) US5618555A (es)
EP (1) EP0680754B1 (es)
JP (1) JP2819236B2 (es)
KR (1) KR950031058A (es)
CN (1) CN1116525A (es)
AT (1) ATE171619T1 (es)
CA (1) CA2147918A1 (es)
DE (1) DE69505041T2 (es)
ES (1) ES2123177T3 (es)
TW (1) TW325406B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3576608B2 (ja) 1994-11-15 2004-10-13 日東電工株式会社 貼付剤および貼付製剤
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
ES2224430T3 (es) * 1997-09-04 2005-03-01 Novoneuron Inc Noribogaina en el tratamiento del dolor y de la toxicomania.
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
AU2001262683A1 (en) * 2000-06-02 2001-12-17 Teijin Limited Buprenorphine-containing patch
KR100448469B1 (ko) * 2001-10-26 2004-09-13 신풍제약주식회사 항염증제의 경피 조성물 및 장치
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
JP4949625B2 (ja) * 2002-06-10 2012-06-13 ユーロ−セルティーク エス．エイ． 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
DE602004009449T2 (de) * 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug
WO2006085521A1 (ja) * 2005-02-10 2006-08-17 Nihon University オピオイドレセプター拮抗剤を含有する経皮吸収用医薬組成物およびその製造方法、並びに前記拮抗剤の経皮吸収促進方法
JPWO2006093066A1 (ja) * 2005-02-28 2008-08-07 久光製薬株式会社 粘着基材及び該粘着基材を含む医療用貼付製剤
EP3434264A1 (en) * 2008-07-18 2019-01-30 Biomod Concepts Inc. Microparticle for releasing an acitve agent
TWI630208B (zh) * 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
CA2806232A1 (en) 2010-07-23 2012-01-26 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
WO2013112673A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Synthetic voacangine
EP2934541A4 (en) 2012-12-20 2016-08-03 Demerx Inc SUBSTITUTED NORIBOGAIN
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
KR20190060007A (ko) * 2016-10-31 2019-05-31 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
JP6695571B2 (ja) * 2016-12-05 2020-05-20 王子ホールディングス株式会社 経皮吸収型製剤
CN109487582A (zh) * 2018-11-19 2019-03-19 长沙浩然医疗科技有限公司 一种纯棉织物面料印染工艺
CN110013602B (zh) * 2019-04-17 2021-10-26 杨高云 用于治疗肢端型白癜风的手套及其制备方法
JP7682995B2 (ja) 2020-07-30 2025-05-26 ダニマー・アイピーシーオー・エルエルシー 消費財包装用バイオベース材料
US11584110B2 (en) 2020-07-30 2023-02-21 Pepsico, Inc. Multi-layered packaging films

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CH672888A5 (es) * 1986-11-07 1990-01-15 Mepha Ag
DE68917292T2 (de) * 1988-02-26 1995-02-02 Riker Laboratories Inc Transdermales estradiol als therapeutisches sytem.
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
ATE95059T1 (de) * 1989-02-28 1993-10-15 Teijin Ltd Pflaster sowie dessen herstellung.
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
ATE148633T1 (de) * 1990-03-28 1997-02-15 Noven Pharma Verfahren und vorrichtung zur freisetzung von arzneimittel an die haut
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions

Also Published As

Publication number Publication date
KR950031058A (ko) 1995-12-18
CA2147918A1 (en) 1995-11-07
DE69505041D1 (de) 1998-11-05
EP0680754B1 (en) 1998-09-30
JP2819236B2 (ja) 1998-10-30
US5618555A (en) 1997-04-08
EP0680754A2 (en) 1995-11-08
CN1116525A (zh) 1996-02-14
ATE171619T1 (de) 1998-10-15
TW325406B (en) 1998-01-21
JPH07304672A (ja) 1995-11-21
DE69505041T2 (de) 1999-02-18
EP0680754A3 (en) 1996-03-06

Similar Documents

Publication Publication Date Title
DE69505041D1 (de) Buprenorphine enthaltendes Präparat für perkutäne Absorption
BR9403783A (pt) Uso de uma composição cosmética
ZA944608B (en) Incorporating poly-N-vinyl amide in a transdermal system
MX9206577A (es) COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES
CA2251331A1 (en) Calcilytic compounds
PT738512E (pt) Utilizacao de um inibidor da hmg-coa-reductase para evitar um segundo ataque cardiaco
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
MX9205389A (es) Composicion farmaceutica que contiene felbinac.
ITMI910584A1 (it) Composizione farmaceutica idrofila contenente ketoprofene sale di lisina per uso topico.
DE69420419D1 (de) Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
PT922453E (pt) Preparacao do tipo de absorcao percutanea contendo tulobuterol
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
NO894465D0 (no) Preparat med oekt penetrasjon gjennom huden.
ES2167338T3 (es) Composicion para tratar pacientes con enfermedades hepaticas.
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
MY118301A (en) Local anesthetic for external use
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
IL95875A0 (en) Illudin analogs,pharmaceutical compositions containing the same and methods for the use thereof
AU5917390A (en) Pharmaceutical composition for topic use for the therapeutical treatment of capillary fragility
JPS6468316A (en) External plaster containing salbutamol
KR970014571A (ko) 1,2-디브로모-2,4-디시아노부탄과 파라하이드록시벤조산 에스테르와의 상승작용성 항미생물성 조성물
CA2170485A1 (en) Compositions Containing an Amino Acid Salt of Propionic Acid Non-Steroidal Anti-Inflammatory Agents and Caffeine
KR910009259A (ko) 천식 또는 특정 피부 질환의 치료를 위한 피리미돈 유도체 및 동족체
EP0348910A3 (en) 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
ATE207357T1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 680754

Country of ref document: ES